Targeted therapies are only effective for a small fraction of cancer patients. We report that FAK inhibitors exert potent anti-tumor effects in NSCLC that express mutant KRAS in association with INK4a/ARF deficiency. These results reveal a novel genotype-specific vulnerability of cancer cells that can be exploited for therapeutic purposes.
INTRODUCTION
Activating mutations of the proto-oncogene KRAS (mutant KRAS) promote tumorigenesis in several common human cancers such as non-small cell lung cancer 4 (NSCLC) (1) . Mutant KRAS exerts its oncogenic activity through the regulation of several signaling networks. Among these, the most extensively characterized are the RAF/MEK/ERK and the PI3K/AKT/mTOR signaling pathways (1, 2) .
In NSCLC, KRAS mutations occur frequently in combination with inactivating mutations or epigenetic silencing of the CDKN2A locus, which encodes two distinct but overlapping tumor suppressors: p19/ARF (p14 in humans, ARF hereafter) and p16/INK4a The genotype of cancer cells not only determines their phenotype, but also defines specific vulnerabilities that can be exploited in cancer therapy. Certain cancers are critically dependent on a single oncogenic activity, a phenomenon defined as oncogene addiction (8) . For instance, continuous expression of mutant KRAS is required for the survival of NSCLC in both mouse cancer models and in human-derived cells (5, 9) .
However, attempts to develop direct inhibitors of mutant KRAS have been unsuccessful (10) . Therefore, mutant KRAS is still a high-priority therapeutic target.
There has been a tremendous interest in identifying molecular targets that are required for the maintenance of mutant KRAS dependent cancers (11) (12) (13) .
Pharmacological inhibitors of MEK1/2, PI3K and/or mTORC1/2 lead to promising antitumor effects in preclinical lung cancer models (14, 15) . In addition, several compounds targeting RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways are currently under 5 clinical investigation and hold promise for the treatment of RAS mutant tumors (16) . On the other hand, it is still unknown whether PI3K and MEK1/2 inhibitors are effective therapies in lung cancer. Thus, it is of interest to develop alternative therapeutic strategies that target mutant KRAS tumors.
The goal of this work was the identification of vulnerabilities of mutant KRAS that can be harnessed for cancer therapy. For this purpose, we dissected the signaling pathways downstream of mutant KRAS in NSCLC developed in a genetically defined mouse model and in cellular systems. With this analysis we determined that the RHOA-FAK signaling axis is a critical vulnerability for high-grade lung tumors.
RESULTS

Deficiency of Cdkn2a leads to aberrant activation of RhoA in Kras
G12D
-induced
NSCLC in vivo
To identify cellular networks required for the maintenance of high-grade lung cancer, we crossed tetracycline operator-regulated Kras G12D (tetO-Kras
G12D
) mice with Clara cell secretory protein-reverse tetracycline transactivator (CCSP-rtTA) mice (5) The RHO family of small GTPases (which comprises RAC, CDC42 and RHO) has been implicated in mutant KRAS induced tumorigenesis. These proteins regulate the cytoskeleton, cell migration, proliferation and survival (20) . RAC1 is required for mutant KRAS induced transformation in fibroblasts in vitro and for initiating tumorigenesis in a mouse model of lung cancer (21, 22) . In addition, Erk1/2 and RhoA regulate common pathways such as cell migration and chemotaxis (23) . Indeed, RHOA is also required for mutant K-RAS induced transformation in vitro (24) . Finally, deregulation of RHOA occurs in a variety of cancer types (25, 26 Supplementary Fig. S2F ).
Research. (Fig. 2C) . Conversely, pharmacological inhibition of MEK1/2 with UO126 and ARRY-142886, lead to down-regulation of RHOA-GTP and consequent up-regulation of RAC1-GTP in H460 and A549 NSCLC cells ( Fig. 2D and Supplementary Fig. S3C ). In agreement with these findings, treatment of
Research. Fig. 2E and 2F ).
Next, we determined the mechanisms underlying p-ERK1/2-dependent upregulation of RHOA-GTP. It has been reported that p-ERK1/2 inhibits p190RHO
GTPase-activating protein (p190RHOGAP), a specific GAP for RHOA, in fibronectinstimulated cells in vitro (31) . We determined whether this mechanism is functionally relevant in NSCLC induced by mutant KRAS. With pulldown assays we detected an increased association of endogenous RHOA-GTP with p190RHOGAP after inhibition of MEK1/2 ( Fig. 2G) . Remarkably, knockdown of p190RHOGAP completely abolished the effect of MEK1/2 inhibition on RHOA (Fig. 2H ). These findings indicate that p-ERK1/2 blocks the ability of p190RHOGAP to interact with RHOA and strongly supports the conclusion that p-ERK1/2 is the major activator of RHOA in this context.
RHOA is a vulnerability of lung cancer cells expressing mutant KRAS
To assess the functional significance of sustained RHOA-GTP in lung adenocarcinomas, we determined the effect of RHOA silencing in cell lines derived from human NSCLC specimens. Remarkably, RHOA silencing with two unrelated siRNAs NSCLC cells we used in vitro. We transduced the A549 cells with a retrovirus expressing RHOA-T19N, a dominant negative mutant of RHOA. Indeed, we found that RHOA-T19N significantly decreases the amount of RHOA-GTP in A549 cells before implantation in mice and in tumors excised at the study endpoint ( Supplementary Fig. S4F ). We detected a greater than 4-fold decrease in tumor formation of xenografts expressing RHOA-T19N
( Fig. 3D and 3E ), which correlated with a dramatic difference in survival (Fig. 3F) . We conclude that activation of RHOA is critical in promoting the growth of NSCLC. increased FAK activation and cell death upon FAK silencing, an effect that was amplified by the knockdown of p53 ( Supplementary Fig. S5D and S5E ).
FAK plays a pivotal role in focal adhesion regulation and turnover in addition to the control of cell adhesion and cancer cell survival (34) (35) (36) (37) . Moreover, it has been demonstrated that, in some cell types, FAK also contributes to actin remodelling by regulating RHOA (38) . Indeed, ablation of FAK in NSCLC cells was accompanied by disruption of focal adhesions, reduced actin stress fiber formation and remarkable upregulation of the p27/Kip1 tumor suppressor ( Fig. 4C and 4D ).
Next, we confirmed that FAK is a physiological target of RHOA in NSCLC cells.
Silencing of RHOA induces a dramatic down-regulation of p-FAK Tyr397 in A549, H460
and H2009 cells (Fig. 4E) . Conversely, forced expression of a constitutively active RHOA mutant (RHOA-Q63L) leads to increased p-FAK Tyr397 ( Supplementary Fig. S5F and S5G). Fig. S6A ).
FAK
Research. Supplementary Fig. S6B ).
Finally, RhoA-GTP strongly co-localizes with p-FAK Tyr397 in mouse lung adenocarcinomas ( Fig. 5C and Supplementary Fig. S6C ).
To assess whether our results are relevant to human NSCLC, we used 120 primary human NSCLC specimens and assessed the mutation status of KRAS together with FAK activation. This analysis revealed an association between mutant KRAS and p-FAK Tyr397 (Fig. 5D ). In addition, we evaluated the activation status of RHOA/FAK and the mutation status of INK4a/ARF and p53 in an independent cohort of 20 consecutive primary human NSCLC specimens expressing mutant KRAS (Table 1 and Supplementary   Fig. S6D, S6E (Supplementary Fig. S7A ).
Remarkably, treatment with PF562271 resulted in significant tumor regression in
Kras
G12D
;Ink4a/Arf -/-mice while it had anti-proliferative effects in Kras
;Ink4a/Arf +/+ mice (Fig. 6A) . Detailed histological evaluation determined that the treatment with PF562271 significantly suppressed the number and size of Kras
;Ink4a/Arf -/-lung adenocarcinomas compared to the placebo-treated mice ( Fig. 6B and 6C ). Lung adenocarcinomas treated with PF562271 were distinguished by the presence of foamy macrophages and enrichment of reparative connective tissue (Fig. 6D upper panels) . In
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on FAK is a positive regulator of Akt (33) . Indeed, we found that PF562271 not only efficiently inhibits FAK Tyr397 in vivo but also results in striking down-regulation of pAkt Ser473 (Fig. 6G) . The anti-tumor effects observed with PF562271 were confirmed with FAK14 inhibitor (Supplementary Fig. S7B-S7G ). FAK14 is structurally unrelated to PF562271 and inhibits the autophosphorylation of FAK at Tyr397 (40).
Finally, we performed studies with A427 and A549 NSCLC cells in order to determine the impact of the PF562271 inhibitor on the survival of athymic nude mice mice carrying xenografts of human cells. Notably, we detected a significant increase in the survival rate of PF562271-treated mice compared to placebo-treated mice ( Fig. 6H and 6I). We obtained similar results with the FAK14 inhibitor ( Supplementary Fig. S7H-S7I ). Thus, we conclude that pharmacological inhibition of FAK is a potent therapeutic strategy for advanced KRAS-induced lung tumors.
DISCUSSION
The identification of patients that may benefit from treatment with targeted cancer therapies is still a significant challenge. In this study, we show that NSCLCs this targeted therapy will have a significant benefit in cancer treatment, the elimination of less-advanced tumors is still an unmet need that must be resolved.
We conclude that the RHOA-FAK signaling axis is a novel, critical synthetic lethal partner of mutant KRAS in NSCLCs that are INK4a/ARF or p53 deficient. We
Research. propose that this information would serve as a biomarker for the selection of patients undergoing personalized cancer treatment protocols involving FAK inhibitors.
MATERIALS AND METHODS
Mouse studies. The PF562271 inhibitor (Pfizer) was reconstituted in 50% DMSO and 50% PEG300 and additionally diluted with saline to a final concentration of 40 mg/kg before administration to the mice twice daily for a total of 12 days by oral gavage. The 
Mutation detection. Mutations were detected using an automated detection pipeline at the Memorial Sloan-Kettering Cancer center Bioinformatics Core. Bi-directional reads and mapping tables (to link read names to sample identifiers, gene names, read direction, and amplicon) were subjected to a QC filter which excludes reads that have an average phred score of < 10 for bases 100-200. See also Supplementary Methods.
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